Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96

Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96

Objectives Cabotegravir + rilpivirine (CAB + RPV) dosed monthly or every 2 months is the first complete long‐acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV‐1 virological suppression. This post hoc analysis summarizes outcomes for Asian participants through week 96...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:HIV medicine 2024-03, Vol.25 (3), p.381-390
Hauptverfasser: Oka, Shinichi, Holohan, Vicki, Shirasaka, Takuma, Choi, Jun Yong, Kim, Yeon‐Sook, Chamay, Nadine, Patel, Parul, Polli, Joseph W., Ford, Susan L., Crauwels, Herta, Garside, Louise, D'Amico, Ronald, Latham, Christine, Solingen‐Ristea, Rodica, Baugh, Bryan, Wyk, Jean
Format: Artikel
Sprache:eng
Schlagworte:
Algorithms
antiretroviral therapy
cabotegravir
Effectiveness
HIV
HIV‐1
Human immunodeficiency virus
long‐acting
Maintenance
Pharmacokinetics
Ribonucleic acid
rilpivirine
RNA
Safety
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives Cabotegravir + rilpivirine (CAB + RPV) dosed monthly or every 2 months is the first complete long‐acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV‐1 virological suppression. This post hoc analysis summarizes outcomes for Asian participants through week 96. Methods Data from Asian participants naive to CAB + RPV randomized to receive dosing every 4 weeks (Q4W) or every 8 weeks (Q8W) in the FLAIR (NCT02938520) and ATLAS‐2M (NCT03299049) phase 3/3b studies were pooled. The proportion of participants with plasma HIV‐1 RNA ≥50 and
ISSN:1464-2662
1468-1293
1468-1293
DOI:10.1111/hiv.13588